1.1 Multi-Organ-Chips I
Monday, 21 September 2015
09:00-10:30
|
| |
|
Six organ chip for substance toxicity testing using Homunculus platform
Dmitry Sakharov, RU-Moscow |
| |
|
Pro-drug activation in a dynamic microfluidic systems interconnecting liver and tumor micro-tissues"
Jens Kelm, CH-Schlieren |
| |
|
Mimicking the cyclic mechanical stress of the lung parenchyma in a breathing lung-on-chip
Janick Stucki, CH-Bern |
1.2 Multi-Organ-Chips II
Monday, 21 September 2015
15:30-17:00
|
| |
|
Microfluidic in vitro platform for parallel human multi-tissue interaction studies
Jin-Young Kim, CH-Zurich |
| |
|
Emulating the human vasculature in a multi-organ-chip platform
Tobias Hasenberg, DE-Berlin |
| |
|
Cryopreserved human hepatocytes and IdMOC experimental system for the evaluation of human drug properties
Albert Li, US-Columbia MD
|
2 Stem Cells
Monday, 21 September 2015
09:00-10:30
|
| |
|
Geometrically confined cell differentiation and migration model for human teratogen detection
Jiangwa Xing, SG-Singapore |
| |
|
Quantitative data on toxicant classification derived from transcriptomics studies of stem cell development
Marcel Leist, DE-Konstanz |
| |
|
Vascular-like network enhances structural and functional maturation of human pluripotent stem sell derived cardiomyocytes in cardiovascular construct
Hanna Vuorenpää, FI-Tampere |
| |
|
Human induced pluripotent stem cells as tools for studying the etiology of Non Alcoholic Fatty Liver Disease
James Adjaye, DE-Düsseldorf |
| |
|
Differentiated human skin-derived stem cells as a novel cell source for in vitro screening of drug-induced liver injury (DILI)
Vera Rogiers, BE-Brussels |
3.1 3D Models I
Sunday, 20 September 2015
16:00-17:30
|
| |
|
Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events
Ellen Fritsche, DE-Düsseldorf |
| |
|
Stem-cell based in vitro models to study human CNS pathophysiology
Zeynab Nayernia, CH-Geneva |
| |
|
The use of the 'Neurosphere-Assay’ to study specific disturbances on FGF-2 function during neurodevelopment
Marta Barenys, DE-Düsseldorf |
| |
|
Assessment of the predictivity of neuronal networks coped to microelectrode arrays for identification of neurotoxicants
Tzutzuy Ramirez, DE-Ludwigshafen |
| |
|
Advances in in vitro testing: the route to replace animal testing
Stella Homer, UK-Rotherham |
3.2 3D Models II
Tuesday, 22 September 2015
13:30-15:00
|
| |
|
The HuALN model for testing immune reactivity in vitro
Christoph Giese, DE-Berlin |
| |
|
Optimization of an eye irritation assay for hazard identification and labelling of materials to address the EU Cosmetic Directive and REACH Legislation
Yulia Kaluzhny, US-Ashland MA |
| |
|
Versatile, polymer-based devices for multi-parameter in vitro toxicology
Roisin Owens, FR-Gardanne |
| |
|
A microfluidics integrated electronic monitoring system of a 3D in vitro model of the renal tubule
Vincenzo Curto, FR-Gardanne |
| |
|
Omnisphero: A novel computational approach for high content image analyses (HCA) of organoid neurosphere cultures in vitro
Martin Roland Schmuck, DE-Düsseldorf |
4 International Progress in 3Rs' research & Global Cooperation on Implementing the 3Rs
Monday, 21 September 2015
13:30-15:00
|
| |
|
Beyond Europe: Accelerating regulatory uptake and use of 3R best practices globally
Troy Seidle, CA-Toronto |
| |
|
EPAA - 10 years of progress and more to do
Renate Weissenhorn, BE-Brussels |
| |
|
The Asian Congress on Alternatives and Animal Use in the Life Sciences 2016
Hajime Kojima, JP-Tokyo |
| |
|
Transatlantic collaboration of Cosmetics Europe with NICEATM/ILS to assess and develop strategy for skin sensitisation safety assessment without animal testing
Sebastian Hoffmann, DE-Paderborn |
| |
|
Decision Algorithm for 3R (Refine, Reduce, Replace) Programs - a case study in vaccines
Iwona Wilk-Zasadna, CH-Basel |
paid advertising
|
5.1 QSAR & Read Across I - Read Across
Tuesday, 22 September 2015
13:30-15:00
|
| |
|
Preventing unnecessary testing by means of read-across: scope, justification and assessment
Karel de Raat, FI-Helsinki |
| |
|
New tools to assist in the application of the read-across approach
Alessandra Roncaglioni, IT-Milano |
| |
|
VPA Read across: Development of predictive biomarkers by using toxicity data of structurally similar compounds
Regina Stöber, DE-Hannover |
| |
|
Metabolomics as a read across tool
Tzutzuy Ramirez, DE-Ludwigshafen |
5.2 QSAR & Read Across II - QSAR
Monday, 21 September 2015
11:00-12:30
|
| |
|
Use of (Q)SARs under REACH - perspective of a regulator
Matthias Herzler, DE-Berlin |
| |
|
Application of in silico methods for predictions of different toxicological endpoints
Malgorzata Drwal, DE-Berlin |
| |
|
QsarDB: solution strategy for efficient use of QSAR models
Uko Maran, EE-Tartu |
| |
|
The Future of the QSAR Toolbox: moving to less uncertainty in predictive toxicology
Romualdo Benigni, IT-Roma |
| |
|
Weighted gene co-expression network analysis to characterize drug induced cardiotoxicity
Jufeng Wang, CN-Beijing |
6 Risk assessment based on the AOP concept
Monday, 21 September 2015
13:30-15:00
|
| |
|
MIEs – the gateways to pathway prediction
Paul Russell, UK-Shambrook |
| |
|
Integration of the epidemiological data with the experimental toxicity studies on pesticides; use of the AOP framework for the definition of biological plausibility
Andrea Terron, IT-Parma |
| |
|
Characterization of the effects of epigallocatechin gallate (EGCG) exposure during neurodevelopment within the AOP concept
Marta Barenys, DE-Düsseldorf |
| |
|
Applying Adverse Outcome Pathways to support Integrated Approaches to Testing and Assessment (IATA)
João Barroso, IT-Ispra |
| |
|
Adverse Outcome Pathway Knowledge Base: A crowdsourcing tool to add value to existing information on Alternative Methods results
Clemens Wittwehr, IT-Ispra |
7 Repeated Dose Toxicity & Other Toxicological Endpoints
Tuesday, 22 September 2015
11:00-12:30
|
| |
|
Towards the replacement of in vivo repeated dose systemic toxicity: Achievements of the SEURAT-1 research initiative
Tilmann Gocht, DE-Tübingen |
| |
|
Metabolomics in vitro: a new approach for systemic toxicity – first applications for mode of action identification and chemical grouping
Tzutzuy Ramirez, DE-Ludwigshafen |
| |
|
28-day microphysiological monitoring of human hepatocellular cells
Joachim Wiest, DE-Munich |
| |
|
Generation of the molecular basis for studying thyroid hormone disruption in neural progenitor cells of humans and rats
Susanne Giersiefer, DE-Düsseldorf |
| |
|
Quantitative analysis of cell migration in the wound healing scratched assay by Using Active Contour Model and Speeded Up Robust Features
Melika Farshad, IR-Shiraz |
| |
|
Failure and Success: in vitro ocular irritation test methods for agrochemical formulations the Bovine Cornea Opacity and Permeability Test and the EpiOcular™ Eye Irritation Test
Susanne Kolle, DE-Ludwigshafen |
8 Inhalation
Tuesday, 22 September 2015
13:30-15:00
|
| |
|
Cellular human based systems for investigating the toxicity effects of inhalable substances
Samuel Constant, CH-Geneva
|
| |
|
Systems Toxicology-based assessment of aerosols using human organotypic tissue cultures of nasal and bronchial epithelium
Julia Hoeng, CH-Lausanne |
| |
|
Characterization of 3D reconstructed human airway models used for biomarker and inflammatory response studies
Rodger Curren, US-Gaithersburg MD |
| |
|
Preliminary validation studies of a 3D in vitro inhalation model, using cytokine and gene expression responses to metal-oxide particles
Ingeborg Kooter, NL-Utrecht |
| |
|
Building a framework of communication between industry and regulators to identify in vitro methods suitable for tobacco regulatory science
Erin Hill, US-Gaithersburg MD |
9.1 Skin Sensitization I
Sunday, 20 September 2015
13:45-15:15
|
| |
|
Outlook on currently available non-animal test methods for skin sensitization testing
Daniel Urbisch, DE-Ludwigshafen |
| |
|
Reconstituted Human Epidermis Models and IL-18 Levels for Identification and Potency Ranking of Skin Sensitizers: Identification of Critical Steps and Harmonization of Existing Protocols for the Purpose of Validation
Erwin Roggen, DK-Bagsvaerd |
| |
|
Evaluating non-animal methods for identifying skin sensitisation hazards: A Bayesian value of information analysis
Maria Leontaridou, DE-Ludwigshafen |
9.2 Skin Sensitization II
Tuesday, 22 September 2015
11:00-12:30
|
| |
|
Towards the assessment of skin sensitization potency: Quantitative estimations by the Direct Peptide Reactivity Assay
Susanne Kolle, DE-Ludwigshafen |
| |
|
From pathways to people: Applying the skin sensitisation AOP to risk assessment
Gavin Maxwell, UK-Shambrook |
| |
|
Functional characterization of reconstructed skin containing in vitro generated Langerhans cells
Günther Weindl, DE-Berlin |
| |
|
Evaluation of an in vitro human dermal sensitization test for use with medical device extracts
Jamin A. Sr. Willoughby, US-Kalamazoo MI |
10.1 Efficacy & Safety Testing I
Tuesday 22 September 2015
09:00-10:30
|
| |
|
A relevant in vitro model for safety testing of chemicals and efficacy testing of pharmaceuticals
Tuula Heinonen, FI-Tampere |
| |
|
Characterization of transporter activities in different cell types by using fluorescent substrates
Anett Ullrich, DE-Schwerin |
| |
|
Development, optimization and standardization of an in vitro skin irritation test for medical devices using the reconstructed human tissue model EpiDerm
Helena Kandarova, SK-Bratislava |
| |
|
HTS for screening of selective muscarinic cholinergic receptors antagonists
Valerii Tonkopii, RU-St. Petersburg
|
10.2 Efficacy & Safety Testing II - Biological and Vaccines
Monday, 21 September 2015
09:00-10:30
|
| |
|
In vitro assays for the potency determination of botulinum neurotoxin serotypes A and B
Emina Wild, DE-Langen |
| |
|
Avian encephalomyelitis live vaccines - alternative methods for batch virus titration
Lena Rimpel, DE-Langen |
| |
|
Pro- and pre-hapten mechanisms in skin sensitization
David Roberts, UK-Liverpool |
| |
|
LLNA variability: an essential ingredient for a comprehensive assessment of non-animal skin sensitisation test methods and strategies
Sebastian Hoffmann, DE-Paderborn |
11 Nano-Toxicology
Monday, 21 September 2015
11:00-12:30
|
| |
|
Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long term opportunities?
Natalie Burden, UK-London |
| |
|
NanoSafety research and its challenges!
Peter Wick, CH-St. Gallen |
| |
|
Cytotoxic and immunological effects of engineered nanomaterials
Marika Mannerstrom, FI-Tampere |
| |
|
Adressing inflammatory parameters of the intestinal mucosa: From the mouse to the test tube
Benno Weigmann, DE-Erlangen |
| |
|
An advanced 3D human epithelial airway model to study the biokinetics of aerosolized biomedical nanoparticles after repeated exposures
Savvina Chortarea, CH-Fribourg |
| |
|
Towards the prediction of nanoparticle-induced inhalation toxicity: Evaluation of an in vitro macrophage assay
Martin Wiemann, DE-Münster |
| |
|
A decision-making framework for the grouping and testing of nanomaterials
|
paid advertising
|
12.1 Disease Models I: CRISPR/Cas
Sunday, 20 September 2015
16:00-17:30
|
| |
|
Scientific and animal welfare issues surrounding the new CRISPR/Cas-9 approach to produce transgenic animals and advanced in vitro disease models
Horst Spielmann, DE-Berlin |
| |
|
CRISPR/Cas-induced structural variants
Malte Spielmann, DE-Berlin |
| |
|
Paving the way to a novel analysis platform to study human diseases
Saniye Sprenger, DE-Berlin |
| |
|
Modeling the air-blood-barrier in state of disease – challenges and perspectives
Marius Hittinger, DE-Saarbrücken |
12.2 Disease Models II: hiPSC
Monday, 21 September 2015
11:00-12:30
|
| |
|
Reconstructed human skin pioneers the implementation of diversity into preclinical testing in vitro
Monika Schäfer-Korting, DE-Berlin |
| |
|
Human stem-cell based functional neuronal in vitro disease models
Susanna Narkilahti, FI-Tampere |
| |
|
Alzheimer's disease research in the 21st century: the shift towards a new paradigm
Francesca Pistollato, US-Washington DC |
| |
|
In vitro hiPSC-based modeling of late-onset disease using progerin-induced aging
Justine Miller, US-Rensselaer NY |
12.3 Disease Models III: Inflammation
Wednesday, 23 September 2015
09:00-10:30
|
| |
|
Modular human biochip-based organoid models in sepsis research
Alexander Mosig, DE-Jena |
| |
|
Use of ex vivo organotypic lung tissue in translational research of respiratory injury and inflammation diseases
Katherina Sewald, DE-Hannover |
| |
|
Evaluation of selumetinib and trametinib MEK inhibitors antitumor efficacy in a preclinical in vitro human lung cancer model
Samuel Constant, CH-Geneva |
| |
|
Phenotypic responses of human asthmatic airway epithelial cultures to rhinovirus and poly(I:C)
Patric Hayden, US-Ashland MA |
| |
|
Small Airway-on-a-Chip: A novel human inflammatory disease model
Kambez Benam, US-Boston MA |
13 Biobarriers
Wednesday, 23 September 2015
11:00-12:30
|
| |
|
Biophysical and metabolic properties of striae distensae evaluated ex vivo compared to normal skin
Youna Coquin, FR-Saint Gregoire |
| |
|
Assess the bio-barrier function of the human respiratory system using an in vitro 3D model of airway epithelial model (MucilAir™)
Samuel Constant, CH-Geneva |
| |
|
Intelligent inserts as scaffolds for functional cell co-culture models on a biomimetic scale
Silvia Angeloni, CH-Neuchâtel |
| |
|
In vitro models of skin wounds – potential, limitations and perspectives
Maike Windbergs, DE-Saarbrücken |
| |
|
Epithelial-endothelal co-cultures to mimic the air-blood-barrier
Brunhilde Blömeke, DE-Trier |
| |
|
What happens when the particle has landed? – In vitro models for studying post-deposition events of aerosolized particles
Marius Hittinger, DE-Saarbrücken |
14 EU Directive 2010/63/EU on the Protection of Animals Used for Scientific Purposes
Monday, 21 September 2015
13:30-15:00
|
| |
|
Directive 2010/63/EU: five years after its adoption
Herman Koeter, NL-Den Haag |
| |
|
Non-technical summaries - a review of EU member states efforts so far
Katy Taylor, UK-London |
| |
|
Different concepts of committees in EU member states, to support the competent authorities performing the project evaluation according to Directive 2010/63/EU
Norbert Alzmann, AT-Vienna |
| |
|
The Role of the National Committee in Germany - Severity Assessment of Genetically Altered Animals
Bettina Bert, DE-Berlin |
| |
|
Legal issues in the work of the German National Committee: an overview
Justyna Chmielewska, DE-Berlin |
15.1 Ethics & Legal Issues I
Monday, 21 September 2015
15:30-17:00
|
| |
|
Pain for Profit. Can monetary reasons justify animal research ethically?
Herwig Grimm, AT-Vienna |
| |
|
Evaluation of the scientific validity of animal experiments in Switzerland
Lucile Vogt, CH-Bern |
| |
|
Implementing the 3Rs: turning words into action
Emily McIvor, UK-Seaton |
15.2 Ethics & Legal Issues II
Tuesday, 22 September 2015
09:00-10:30
|
| |
|
Update on 3Rs activities at the EU institutional level and beyond the borders
Francois Busquet, BE-Brussels |
| |
|
40 years of Animalfree Research. Results and lessons learned from a quality assessment
Stefanie Schindler, CH-Zurich |
| |
|
Non-animal Testing: It’s within REACH
Julia Baines (replacing Gilly Stoddart), UK-Colchester |
| |
|
REACH, the Cosmetics Regulation and upholding the animal testing ban
Julia Baines, UK-Colchester |
| |
|
Harm-benefit analysis of animal experimentation: a qualitative study of ethics committee practice in six European countries
Anna Olsson, PT-Porto |
16.1 Refinement I and Culture of Care
Tuesday, 22 September 2015
15:30-17:00
|
| |
|
Working together to develop and implement a 'culture of care'
Kirsty Reid, BE-Brussels |
| |
|
Pain Management and post-operative monitoring and care of laboratory rodents in Germany – lessons learnt and recommendations to improve practice
Kathrin Herrmann, DE-Berlin |
| |
|
Ending severe suffering: the scientific animal welfare organization as a catalyst for change
Elliot Lilley, UK-Horsham |
| |
|
Refinement facilitated by the Culture of Care
Susanna Louhimies, BE-Brussels |
16.2 Refinement II
Tuesday, 22 September 2015
11:00-12:30
|
| |
|
Barriers to the implementation of refinements in animal laboratories
Katy Taylor, UK-London |
| |
|
Refinement strategies in experimental autoimmune encephalomyelitis (EAE) in mice
Kristina Ullmann, DE-Berlin |
| |
|
Community guidelines on animal studies - ALS research as a case-study
Nuno Henrique Franco, PT-Porto |
| |
|
The role of the animal welfare officer on the 3R´s principle in laboratory animal science in Germany
Christa Thöne-Reineke, DE-Berlin |
| |
|
Ethics review of animal experiments in Europe under Directive 2010/63/EU
Anna Olsson, PT-Porto |
17.1 Replacement I
Tuesday, 22 September 2015
09:00-10:30
|
| |
|
Animals are not 'Materials and Methods': Why it is important to focus on Replacement
Candida Nastrucci, IT-Rome |
| |
|
Examination of human bone tissue regeneration using the chorioallantoic membrane (CAM): an ex vivo replacement model for animal research
Ines Moreno, UK-Southampton |
| |
|
Strategies for combining skin and vasculature in a Multi-Organ-Chip Platform
Katharina Schimek, DE-Berlin |
| |
|
Stem cell-derived human dorsal root ganglia-like cells to identify peripheral neurotoxicants
Lisa Hoelting, DE-Konstanz |
| |
|
Functional neurons from cancer cells: a novel in vitro model exhibits appropriate functional parameters
Susanna Alloisio, IT-Genoa |
17.2 Replacement II
Tuesday, 22 September 2015
15:30-17:00
|
| |
|
3D biocompatibility test systems mimicking the in vivo situation: evaluation of a hydroxyapatite-nanoparticular paste
Veronika Hruschka, AT-Vienna |
| |
|
A mismatch between micro-motives and macro-behaviour: The inefficiency of efforts toward replacement at the individual level
Jan Lauwereyns, JP-Fukuoka |
| |
|
New guidance on information requirements for skin corrosion/irritation and serious eye damage/eye irritation under REACH
Bohumila Bichlmaier Suchanová, FI-Helsinki |
| |
|
Replacement – coming closer to a dream
Thomas Hartung, US-Baltimore MD |
18.1 3Rs in Academia & Education I
Sunday, 20 September 2015
13:45-15:15
|
| |
|
The Berlin-Brandenburg Research Platform BB3R and integrated graduate school
Monika Schäfer-Korting, DE-Berlin |
| |
|
CERST-NRW: a German state government of North Rhine Westphalia-funded initiative for the development of alternative methods to animal testing
Ellen Fritsche, DE-Düsseldorf |
| |
|
Teaching alternative methods in toxicology in veterinary science
Francesca Caloni, IT-Milano |
| |
|
Romanian Center for Alternative Test Methods (ROCAM) – a newly established 3Rs Center to promote and support the alternative methods field in Romania
Lucian Farcal, RO-Cluj-Napoca |
| |
|
CAAT-Europe and knowledge exchange on the progress of the 3Rs and research methods
Marcel Leist, DE-Konstanz |
18.2 3Rs in Academia & Education II
Monday, 21 September 2015
15:30-17:00
|
| |
|
Reboot3R - Design Thinking Workshops for scientists to constructively find ways to apply 3Rs within their own career
Cecilia Hilmer, DE-Berlin |
| |
|
Animal Research: critical, challenging & creative thinking about the 3Rs
Juliet Dukes, UK-Southwater |
| |
|
A Course in Alternatives: focus on replacement and non-animal methods
Candida Nastrucci, IT-Rome |
| |
|
Follow-up on 2013 EUSAAT’s Congress and its impact for Sri Lankan scientific community in 3Rs
Mangala Gunatilake, LK-Colombo |
| |
|
Improving animal welfare through competence: The EUPRIM-Net education and training programs
Valeska Marija Stephan, DE-Göttingen |
| |
|
Refinement of welfare through application of a quantitative system for assessment of lifetime experience
Michael Dennis, UK-Salisbury |
| |
|
Journal policies on animal use – current landscape and future directions
Nuno Henrique Franco, PT-Porto |
19.1 Young Scientists Short Lectures I
Tuesday, 22 September 2015
15:30-17:00
|
| |
|
A 3D in vitro iPSC derived mini-brain model to study Parkinson’s disease
David Pamies, US-Baltimore MD |
| |
|
Molecular modelling of osteoarthritis – evaluating pathways in vitro
Annemarie Lang, DE-Berlin |
| |
|
A novel human organotypic tumor invasion model of cell line MDA-MB-231 in Precision-Cut Lung Slices (PCLS) to reduce animal experiments in preclinical oncology
Sebastian Konzok, DE-Hannover |
| |
|
Impaired skin barrier function of cutaneous squamous cell carcinoma
Christopher Wolff, DE-Berlin |
| |
|
Generation of 3D neurospheres from human induced pluripotent stem cells as an alternative in vitro method to study neurodevelopmental defects of Cockayne Syndrome patient
Maxi Hofrichter, DE-Düsseldorf |
| |
|
Human lymphoblastoid cell lines as an in vitro tool in preclinical drug evaluation
Tijana Markovic, SI-Ljubljana |
| |
|
Systematic assessment of different computational approaches for prediction of toxic effects of new chemical structures
Priyanka Banerjee, DE-Berlin |
19.2 Young Scientists Short Lectures II
Wednesday, 23 September 2015
11:00-12:30
|
| |
|
Chip-based co-culture of neurospheres and liver spheroids for long-term substance testing
Anja Ramme, DE-Spreenhagen |
| |
|
Human in vitro Blood-Brain Barrier model generated from stem cells: reducing attrition in the Central Nervous System area
Aurore Drolez, FR-Lens |
| |
|
A microfluidic four-organ-chip – a potential tool for ADME profiling
Juliane Hübner, DE-Berlin |
| |
|
In vitro investigation on uptake, cytotoxicity and genotoxicity of two similar sized titanium oxide nanoparticles on the human hepatic cells HepaRG
Pegah Jalili, FR-Fougeres |
| |
|
Optimization of a new in vitro method for inhalation toxicology and its application for the study of zinc oxide nanoparticle toxicity
Emilie Da Silva, DK-København |
| |
|
Assessment of sensitization and photosensitization of benzophenone-3 based on DPRA
Carolina Benevenuto, BR-Brazil |
